BRAF mutation assessment in papillary thyroid cancer: Are we ready to use it in clinical practice?

Endocrine

Volumn 45, Issue 3, 2014, Pages 341-343

  Puxeddu, Efisio ^a   Filetti, Sebastiano ^b  

^a UNIVERSITY OF PERUGIA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; PLACEBO; RADIOACTIVE IODINE; SORAFENIB; VEMURAFENIB; BIOLOGICAL MARKER; BRAF PROTEIN, HUMAN;

ABLATION THERAPY; ALLELE; BRAF GENE; CANCER MORTALITY; EDITORIAL; FINE NEEDLE ASPIRATION BIOPSY; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; MELANOMA; METASTASIS; MUTATIONAL ANALYSIS; ONCOGENE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PYROSEQUENCING; RECURRENT DISEASE; THYROID PAPILLARY CARCINOMA; CARCINOMA; GENETICS; MUTATION; THYROID NEOPLASMS;

BIOLOGICAL MARKERS; CARCINOMA; HUMANS; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; THYROID NEOPLASMS;

EID: 84897030769     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-013-0139-0     Document Type: Editorial

References (20)

1. H. Davies, G.R. Bignell, C. Cox, P. Stephens, S. Edkins, S. Clegg, J. Teague, H. Woffendin, M.J. Garnett, W. Bottomley, N. Davis, E. Dicks, R. Ewing, Y. Floyd, K. Gray, S. Hall, R. Hawes, J. Hughes, V. Kosmidou, A. Menzies, C. Mould, A. Parker, C. Stevens, S. Watt, S. Hooper, R. Wilson, H. Jayatilake, B.A. Gusterson, C. Cooper, J. Shipley, D. Hargrave, K. Pritchard-Jones, N. Maitland, G. Chenevix-Trench, G.J. Riggins, D.D. Bigner, G. Palmieri, A. Cossu, A. Flanagan, A. Nicholson, J.W. Ho, S.Y. Leung, S.T. Yuen, B.L. Weber, H.F. Seigler, T.L. Darrow, H. Paterson, R. Marais, C.J. Marshall, R. Wooster, M.R. Stratton, P.A. Futreal, Mutations of the BRAF gene in human cancer. Nature 417, 949-954 (2002)
2. M. Xing, BRAF mutation in thyroid cancer. Endocr. Relat. Cancer 12, 245-262 (2005)
3. E. Tiacci, V. Trifonov, G. Schiavoni, A. Holmes, W. Kern, M.P. Martelli, A. Pucciarini, B. Bigerna, R. Pacini, V.A. Wells, P. Sportoletti, V. Pettirossi, R. Mannucci, O. Elliott, A. Liso, A. Ambrosetti, A. Pulsoni, F. Forconi, L. Trentin, G. Semenzato, G. Inghirami, M. Capponi, F. Di Raimondo, C. Patti, L. Arcaini, P. Musto, S. Pileri, C. Haferlach, S. Schnittger, G. Pizzolo, R. Foa, L. Farinelli, T. Haferlach, L. Pasqualucci, R. Rabadan, B. Falini, BRAF mutations in hairy-cell leukemia. N. Engl. J. Med. 364, 2305-2315 (2011)
4. M.N. Nikiforova, E.T. Kimura, M. Gandhi, P.W. Biddinger, J.A. Knauf, F. Basolo, Z. Zhu, R. Giannini, G. Salvatore, A. Fusco, M. Santoro, J.A. Fagin, Y.E. Nikiforov, BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J. Clin. Endocrinol. Metab. 88, 5399-5404 (2003)
5. J.C. Ricarte-Filho, M. Ryder, D.A. Chitale, M. Rivera, A. Heguy, M. Ladanyi, M. Janakiraman, D. Solit, J.A. Knauf, R.M. Tuttle, R.A. Ghossein, J.A. Fagin, Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res. 69, 4885-4893 (2009)
6. E. Puxeddu, C. Durante, N. Avenia, S. Filetti, D. Russo, Clinical implications of BRAF mutation in thyroid carcinoma. Trends Endocrinol. Metab. 19, 138-145 (2008)
7. A. Guerra, M.R. Sapio, V. Marotta, E. Campanile, S. Rossi, I. Forno, L. Fugazzola, A. Budillon, T. Moccia, G. Fenzi, M. Vitale, The primary occurrence of BRAF(V600E) is a rare clonal event in papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 97, 517-524 (2012)
8. R.A. Ghossein, N. Katabi, J.A. Fagin, Immunohistochemical detection of mutated BRAF V600E supports the clonal origin of BRAF-induced thyroid cancers along the spectrum of disease progression. J. Clin. Endocrinol. Metab. 98, E1414-E1421 (2013)
9. N. Nasrollah, P. Trimboli, L. Guidobaldi, D.D. Cicciarella Modica, C. Ventura, G. Ramacciato, S. Taccogna, F. Romanelli, S. Valabrega, A. Crescenzi, Thin core biopsy should help to discriminate thyroid nodules cytologically classified as indeterminate. A new sampling technique. Endocrine 43, 565-659 (2013)
10. P. Trimboli, R. Guglielmi, S. Monti, I. Misischi, F. Graziano, N. Nasrollah, S. Amendola, S.N. Morgante, M.G. Deiana, S. Valabrega, V. Toscano, E. Papini, Ultrasound sensitivity for thyroid malignancy is increased by real-time elastography: a prospective multicenter study. J. Clin. Endocrinol. Metab. 97, 4524-4530 (2012)
11. E.K. Alexander, G.C. Kennedy, Z.W. Baloch, E.S. Cibas, D. Chudova, J. Diggans, L. Friedman, R.T. Kloos, V.A. LiVolsi, S.J. Mandel, S.S. Raab, J. Rosai, D.L. Steward, P.S. Walsh, J.I. Wilde, M.A. Zeiger, R.B. Lanman, B.R. Haugen, Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N. Engl. J. Med. 367, 705-715 (2012)
12. M. Xing, BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr. Rev. 28, 742-762 (2007)
13. M. Xing, A.S. Alzahrani, K.A. Carson, D. Viola, R. Elisei, B. Bendlova, L. Yip, C. Mian, F. Vianello, R.M. Tuttle, E. Robenshtok, J.A. Fagin, E. Puxeddu, L. Fugazzola, A. Czarniecka, B. Jarzab, C.J. O'Neill, M.S. Sywak, A.K. Lam, G. Riesco-Eizaguirre, P. Santisteban, H. Nakayama, R.P. Tufano, S.I. Pai, M.A. Zeiger, W.H. Westra, D.P. Clark, R. Clifton-Bligh, D. Sidransky, P.W. Ladenson, V. Sykorova, Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA 309, 1493-1501 (2013)
14. C. Durante, E. Puxeddu, E. Ferretti, R. Morisi, S. Moretti, R. Bruno, F. Barbi, N. Avenia, A. Scipioni, A. Verrienti, E. Tosi, A. Cavaliere, A. Gulino, S. Filetti, D. Russo, BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J. Clin. Endocrinol. Metab. 92, 2840-2843 (2007)
15. M. Xing, B.R. Haugen, M. Schlumberger, Progress in molecular-based management of differentiated thyroid cancer. Lancet 381, 1058-1069 (2013)
16. C. Li, P. Aragon Han, K.C. Lee, L.C. Lee, A.C. Fox, T. Beninato, M. Thiess, B.M. Dy, T.J. Sebo, G.B. Thompson, C.S. Grant, T.J. Giordano, P.G. Gauger, G.M. Doherty, T.J. Fahey III, J. Bishop, J.R. Eshleman, C.B. Umbricht, E.B. Schneider, M.A. Zeiger, Does BRAF V600E mutation predict aggressive features in papillary thyroid cancer? Results from four endocrine surgery centers. J. Clin. Endocrinol. Metab. 98, 3702-3712 (2013)
17. D. Barbaro, R.M. Incensati, G. Materazzi, G. Boni, M. Grosso, E. Panicucci, P. Lapi, C. Pasquini, P. Miccoli, The BRAF V600E mutation in papillary thyroid cancer with positive or suspected pre-surgical cytological finding is not associated with advanced stages or worse prognosis. Endocrine (2013)
18. E. Puxeddu, S. Romagnoli, M.E. Dottorini, Targeted therapies for advanced thyroid cancer. Curr. Opin. Oncol. 23, 13-21 (2011)
19. M.S. Brose, C. Nutting, B. Jarzab, R. Elisei, S. Siena, L. Bastholt, C. de la Fouchardiere, F. Pacini, R. Paschke, Y.K. Shong, S.I. Sherman, J.W.A. Smit, J.W. Chung, H. Siedentop, I. Molnar, M. Schlumberger, Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: the phase III DECISION trial. J. Clin. Oncol. 31(Suppl, Abstract 4) (2013)
20. K.B. Kim, M.E. Cabanillas, A.J. Lazar, M.D. Williams, D.L. Sanders, J.L. Ilagan, K. Nolop, R.J. Lee, S.I. Sherman, Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation. Thyroid 23, 1277-1283 (2013)